doi:10.1093/ajcn/69.6.1135 Birkeland E, Gharagozlian S, Gulseth HL, Birkeland KI, Hartmann B, Holst JJ, et al
Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus
In terms of its effects, it appears to impact drinking in ways (though not necessarily mechanisms) similar to naltrexone (FDA-approved) and topiramate (prescribed off label for alcohol use disorder), which have a greater effect in reducing intensity of drinking on drinking days relative to their effects on whether someone drinks at all (i.e., abstinent days) although all of them do increase abstinent days to some degree on average)
Modulation of other neurohormonal pathways, such as the renin-angiotensin system, may also contribute to cardiovascular effects, potentially leading to improved vascular function and reduced blood flow resistance